1. Grill S. et al., Smoking and physical inactivity increase cancer prevalence in BRCA-1 and BRCA-2 mutation carriers: results from a retrospective observational analysis. Arch Gynecol Obstet. 2017;296(6): 1135-1144.

2. Kiechle M. et al., Feasibility of structured endurance training and Mediterranean diet in BRCA1 and BRCA2 mutation carriers - an interventional randomized controlled multicenter trial (LIBRE-1). BMC Cancer. 2017;17(1): 752.

3. Hamdi Y. et al., Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Res Treat. 2017;161(1): 117-134.

4. Hahnen E. et al., Germline Mutations in Triple-Negative Breast Cancer. Breast Care OR. 2017;12(1): 15-19.

5. Meier F. et al., Entitlement to prophylactic treatment in cases of genetic predisposition for breast cancer : Interdisciplinary perspectives. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017;60(10): 1102-1108.

6. Amos CI. et al., The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. Cancer Epidemiol Biomarkers Prev. 2017;26(1): 126-135.

7. Yang R. et al., The association between breast cancer and S100P methylation in peripheral blood by multicenter case-control studies. Carcinogenesis. 2017;38(3): 312-320.

8. Neidhardt G. et al, The RAD51C exonic splice-site mutations c.404G>C and c.404G>T are associated with familial breast and ovarian cancer. Eur J Cancer Prev. 2017;26(2): 165-169.

9. Walker LC. et al., Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. Eur J Hum Genet. 2017;25(4): 432-438.

10. Muranen TA. et al., Genetic modifiers of CHEK2*1100delC-associated breast cancer risk. Genet Med. 2017;19(5): 599-603.

11. Feng YA. et al., Investigating the genetic relationship between Alzheimer's disease and cancer using GWAS summary statistics. Hum Genet. 2017;136(10): 1341-1351.

12. Lecarpentier J. et al., Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. J Clin Oncol. 2017;35(20): 2240-2250.

13. Kuchenbaecker KB. et al., Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst. 2017;109(7).

14. Kuchenbaecker KB. et al., Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23): 2402-2416.

15. Hahnen E. et al., Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. JAMA Oncol. 2017;3(10): 1378-1385.

16. Neidhardt G. et al., Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer. JAMA Oncol. 2017;3(9): 1245-1248.

17. Milne RL. et al., Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet. 2017;49(12): 1767-1778.

18. Phelan CM. et al., Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017;49(5): 680-691.

19. Michailidou K. et al., Association analysis identifies 65 new breast cancer risk loci. Nature. 2017;551(7678): 92-94.

20. Jiao X. et al., PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1. Oncotarget. 2017;8(61): 102769-102782.

21. Harter P. et al., Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). PLoS ONE. 2017;12(10): e0186043.